生物活性：Lurbinectedin-d3 is deuterium labeled Lurbinectedin. Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively[1].
Clinical Trial
NCT NumberSponsorConditionStart DatePhaseNCT05063318PharmaMarAdvanced Solid TumorsOctober 7, 2020Phase 1NCT05734066Jazz PharmaceuticalsRefractory Ewing Sarcoma|Relapsed Ewing Sarcoma|Ewing SarcomaMay 23, 2023Phase 1|Phase 2NCT05876715ERLINDA M GORDON|Sarcoma Oncology Research Center, LLCAdvanced Soft-tissue SarcomaJune 7, 2023Phase 1|Phase 2 NCT05229588HonorHealth Research Institute|Jazz PharmaceuticalsPancreas CancerJune 14, 2022Phase 2NCT00877474PharmaMarADVANCED SOLID TUMORSMarch 2009Phase 1NCT05574504AdventHealth|Jazz PharmaceuticalsMetastatic Cancer|Urothelial CarcinomaMay 8, 2023Phase 2NCT05153239PharmaMarRelapsed Small Cell Lung CancerJuly 22, 2022Phase 3NCT04291937Jazz PharmaceuticalsSmall Cell Lung CancerNCT05126433Jazz PharmaceuticalsAdvanced Solid Tumor|Metastatic Solid Tumor|Urothelial Cancer|Poorly Differentiated Neuroendocrine Carcinomas|Homologous Recombination Deficient-Positive Malignancies AgnosticMarch 3, 2022Phase 2NCT05578326UNC Lineberger Comprehensive Cancer Center|G1 Therapeutics, Inc.Lung Cancer|Small-cell Lung CancerOctober 12, 2022Phase 2NCT05072106PharmaMarAdvanced Solid TumorJanuary 14, 2021Phase 1NCT04610658H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Jazz PharmaceuticalsSmall-cell Lung Cancer|Relapsed Small Cell Lung Cancer|Recurrent Small Cell Lung CancerNovember 23, 2020Phase 1|Phase 2NCT01970540PharmaMarEndometrial Adenocarcinomas|Neuroendocrine Tumors|Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of TherapyMay 25, 2011Phase 1NCT01831089PharmaMarBreast Cancer|Ovarian Cancer|Gynecological Cancer|Head and Neck Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Non-squamous Cell Lung CancerSeptember 2013Phase 1NCT01525589PharmaMarBreast CancerJune 13, 2012Phase 2NCT04607954Mayo ClinicPlatinum-Resistant Lung Small Cell Carcinoma|Platinum-Sensitive Lung Small Cell Carcinoma|Recurrent Extensive Stage Lung Small Cell Carcinoma|Refractory Extensive Stage Lung Small Cell CarcinomaDecember 4, 2020Phase 2NCT05800587Fox Chase Cancer CenterLung Cancer|Small-cell Lung Cancer|Non Small Cell Lung CancerFebruary 22, 2023Phase 2NCT02210364PharmaMarMetastatic Breast Cancer|Pancreatic Cancer|Metastatic Colorectal CancerApril 2013Phase 1NCT04638491Luye Pharma Group Ltd.Advanced Solid TumorOctober 24, 2020Phase 1NCT02566993PharmaMarSmall-cell Lung CancerAugust 30, 2016Phase 3NCT05740566AmgenSmall Cell Lung Cancer (SCLC)May 31, 2023Phase 3NCT05101265PharmaMarAdvanced Solid Tumor|Hepatic ImpairmentMarch 9, 2021Phase 1NCT02684318Poveda, Andrés, M.D.|AstraZeneca|PharmaMarAdvanced Cancer|Ovarian Cancer|Endometrial Cancer|Breast CancerJuly 2015Phase 1|Phase 2NCT05918640Children´s Hospital of Philadelphia|Jazz Pharmaceuticals|Stand Up To CancerEwing Sarcoma|Desmoplastic Small Round Cell Tumor|Pediatric Cancer|Undifferentiated SarcomaJuly 27, 2023Phase 1|Phase 2NCT02454972PharmaMarAdvanced Solid TumorsAugust 25, 2015Phase 2NCT05099666Massachusetts General Hospital|Jazz PharmaceuticalsAdvanced Soft-tissue Sarcoma|Metastatic Soft-tissue Sarcoma|Advanced Leiomyosarcoma|Leiomyosarcoma MetastaticFebruary 4, 2022Phase 1|Phase 2NCT05636111M.D. Anderson Cancer Center|Jazz PharmaceuticalsOvarian CancerMay 31, 2023Phase 1NCT05244239Emory University|National Cancer Institute (NCI)|Jazz PharmaceuticalsExtensive Stage Lung Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8July 27, 2022Phase 1NCT05042934M.D. Anderson Cancer Center|National Cancer Institute (NCI)Metastatic Ewing Sarcoma|Recurrent Ewing SarcomaSeptember 15, 2021Phase 1|Phase 2NCT01314599PharmaMarAcute LeukemiaMay 2011Phase 1NCT04358237Antonio Calles Blanco|MedSIR|PharmaMar|Merck Sharp & Dohme LLC|Blanco, Dr Antonio Calles MDSmall Cell Lung CarcinomaSeptember 21, 2020Phase 1|Phase 2NCT05285033Intergroupe Francophone de Cancerologie Thoracique|Groupe Français de Pneumo-Cancérologie|PharmaMarSmall-cell Lung CancerApril 1, 2022NCT02451007PharmaMarSolid TumorsAugust 12, 2015Phase 2NCT02448537Massachusetts General Hospital|Dana-Farber Cancer Institute|PharmaMarMetastatic SarcomaAugust 2015Phase 2NCT05572476Institut Bergonié|AstraZeneca|PharmaMarSmall Cell Lung Cancer|Platinum-Sensitive Lung Small Cell Carcinoma|Extensive-stage Small-cell Lung CancerApril 2023Phase 2NCT01980667PharmaMarAdvanced Solid TumorsJuly 30, 2014Phase 1NCT02421588PharmaMarOvarian CancerMay 2015Phase 3NCT02611024PharmaMarAdvanced Solid Tumors|Glioblastoma|Soft Tissue Sarcoma (Excluding GIST)|Endometrial Carcinoma|Epithelial Ovarian Carcinoma|Mesothelioma|Gastroenteropancreatic Neuroendocrine Tumor|SCLC|Gastric Carcinoma|Pancreatic Adenocarcinoma|Colorectal Carcinoma|Neuroendocrine TumorsMay 6, 2016Phase 1|Phase 2NCT01951157PharmaMarNon-Small Cell Lung Cancer (NSCLC)September 11, 2013Phase 2NCT04802174National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)SCLC|Small Cell Cancer|Advanced Solid Tumor|High Grade Neuroendocrine CancersJune 1, 2021Phase 1|Phase 2NCT01970553PharmaMarSpecific Advanced Solid TumorsMay 2011Phase 1NCT03213301Swiss Group for Clinical Cancer ResearchMalignant Pleural Mesothelioma, AdvancedSeptember 28, 2017Phase 2NCT04253145Fundacion OncosurCarcinoma, Small Cell LungDecember 13, 2019Phase 1NCT01405391PharmaMarMajor Advanced Solid Tumors Other Than ColorectalNovember 2011Phase 1NCT05091567Hoffmann-La Roche|Jazz PharmaceuticalsSmall-Cell Lung CancerNovember 18, 2021Phase 3
分子量：787.89
Formula：C41H41D3N4O10S
非标记 CAS：497871-47-3
性状：固体
颜色：Colorless to light yellow
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：-20°C, protect from light, stored under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)